Search Results - Hun Ju Lee

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Effects of psychological symptoms on life adjustment among survivors of humidifier disinfectants by Min Joo Lee, Soeun Hong, Yubin Jung, Hun-Ju Lee, Sang Min Lee

    Get full text
    Article


  2. 2

    P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center e... by Serageldin Kamel, Lucia Martiniova, Eslam Aboismail, Joo Schmidt, Sairah Ahmed, Ranjit Nair, Raphael E. Steiner, Michael L. Wang, Sarita Soebianto, Gregory Ravizzini, Tinsu Pan, Hun Ju Lee

    Published in HemaSphere (2022-10-01)
    Get full text
    Article


  3. 3

    ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study by Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis E Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham H. Wilson, Andre Goy, Anas Younes, Hun Ju Lee

    Published in Haematologica (2019-02-01)
    Get full text
    Article


  4. 4

    Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes? by Jillian R. Gunther, Chelsea C. Pinnix, Gordon R. Glober, Kaitlin M. Christopherson, Penny Fang, Hun Ju Lee, Sairah Ahmed, Raphael E. Steiner, Ranjit Nair, Paolo Strati, Sattva S. Neelapu, Loretta J. Nastoupil, Bouthaina S. Dabaja

    Published in eJHaem (2020-07-01)
    Get full text
    Article


  5. 5

    A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas by Paolo Strati, Loretta J. Nastoupil, Richard E Davis, Luis E. Fayad, Nathan Fowler, Fredrick B. Hagemeister, Larry Kwak, Yasuhiro Oki, Michael Wang, Jason Westin, Charnelle E. Ruben, Emily T. Wesson, Richard Piekarz, Michelle A. Fanale, Hun Ju Lee

    Published in Haematologica (2020-01-01)
    Get full text
    Article


  6. 6

    Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma by Matthew Mei, Joycelynne Palmer, Hun Ju Lee, Iris Isufi, Robert Chen, Ni‐Chun Tsai, Saro Armenian, James Godfrey, Joo Y. Song, John H. Baird, Swetha Thiruvengadam, Yazeed Samara, Jessica Flores, Lacolle Peters, Steven Rosen, Larry Kwak, Stephen J. Forman, Alex F. Herrera

    Published in HemaSphere (2025-05-01)
    Get full text
    Article


  7. 7

    P1064: BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 S... by Chris Yasenchak, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Linda Ho, Michelle Fanale, Wenchuan Guo, Hun Ju Lee

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  8. 8

    Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas by Thomas F Gajewski, John A Thompson, Sanjay Goel, Brendan D Curti, Elisabeth I Heath, Olivier Rixe, David C Smith, Celine Jacquemont, Tycel Phillips, Martin Gutierrez, Sahar Ansari, Andrew L Coveler, Svetomir N Markovic, Timothy M Kuzel, Amitkumar N Mehta, David L Bajor, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson

    Published in Journal for ImmunoTherapy of Cancer (2023-06-01)
    Get full text
    Article


Search Tools: